Papers - TANAKA Hisashi
-
Efficacy and safety findings of the EXTRA study in older adult EGFR-mutant lung cancer patients receiving afatinib as first-line treatment.
Morikawa K, Takata S, Tanaka H, Itani H, Ishihara M, Horiuchi K, Kato Y, Ikemura S, Nakagawa H, Nakahara Y, Seki Y, Bessho A, Takahashi N, Hayashi K, Endoh T, Takeyama K, Maekura T, Takigawa N, Kawase A, Endoh M, Nemoto K, Kishi K, Soejima K, Okuma Y, Yoshimura K, Saigusa D, Kanai Y, Ueda K, Togashi A, Matsutani N, Seki N
Scientific reports 16 ( 1 ) 2026.2
-
The gut microbiota as a potential biomarker in patients with EGFR-mutant lung cancer.
Tabe C, Motooka D, Fujita T, Makiguchi T, Taima K, Tanaka H, Itoga M, Ishioka Y, Akita T, Ishidoya M, Chubachi K, Fukushima T, Tanaka Y, Odagiri H, Kameyama Y, Kobori Y, Tasaka S, Fujii H
Scientific reports 16 ( 1 ) 1672 2025.12
-
Analysis of Poor Prognostic Factors and Treatment Strategies in Platinum-Based Systemic Therapy After EGFR-TKI Failure in Patients With Advanced Nonsmall Cell Lung Cancer Harboring EGFR Mutations.
Hata T, Yamada T, Furuya N, Tanaka H, Yoshimura A, Oba T, Hibino M, Fukuda T, Goto Y, Nakao A, Ogusu S, Okazaki Y, Harada T, Ota T, Masubuchi K, Mikami K, Matsumoto S, Honda R, Date K, Chihara Y, Kawachi H, Morimoto K, Takayama K.
Clin Lung Cancer. 2025.12
-
Efficacy and safety of immune checkpoint inhibitors in advanced non-small cell lung cancer with idiopathic interstitial pneumonia or interstitial lung abnormalities: NJLCG2301.
Okumura F, Tanaka H, Onodera K, Morita R, Inomata M, Suzuki A, Sugisaka J, Minemura H, Jingu D, Kudo S, Kikuchi H, Yoshimura N, Tsushima F, Kakeda S, Tasaka S
Translational lung cancer research 14 ( 11 ) 4756 - 4767 2025.11
-
Reversible ST-T Segment Changes Induced by Anamorelin: A Case Report.
Akaishi H, Makiguchi T, Ishida Y, Shimanaka T, Tanaka H, Taima K, Tasaka S
Respirology case reports 13 ( 11 ) e70398 2025.11
-
A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study.
Hiromi Nagashima, Tatsuro Fukuhara, Yu Utsumi, Aya Suzuki, Akihiko Miyanaga, Masahiro Seike, Koichi Azuma, Hajime Asahina, Akira Kisohara, Yosuke Kawashima, Hisashi Tanaka, Ryota Kanemaru, Eisaku Miyauchi, Naoki Furuya, Haruna Sato, Kazuhisa Nakashima, Satoshi Watanabe, Kazuko Sakai, Kazuto Nishio, Fumiaki Takahashi, Kunihiko Kobayashi, Makoto Maemondo
European journal of cancer (Oxford, England : 1990) 229 115693 - 115693 2025.10
-
Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study.
Morimoto K, Yamada T, Furuya N, Tanaka H, Yoshimura A, Oba T, Hibino M, Fukuda T, Goto Y, Nakao A, Ogusu S, Okazaki Y, Harada T, Ota T, Masubuchi K, Mikami K, Hata T, Matsumoto S, Honda R, Date K, Chihara Y, Takayama K
International journal of clinical oncology 30 ( 10 ) 1963 - 1971 2025.10
-
Cyclical Hemoptysis in a Patient With Right Lower Lobe Opacity Published online
Shintaro Oyama, Tomonori Makiguchi, Yasuhito Nunomura; Shunta Mukai Kengo Tani, Takahiro Sasaki, Daisuke Kimura, Masamichi Itoga, Hisashi Tanaka, Kageaki Taima, Sadatomo Tasaka.
CHEST® Pulmonary 2025.9
-
A Case of ATTR Amyloidosis Diagnosed Using Transbronchial Lung Biopsy Without Abnormal CT Findings
Kobori Yuri, Taima Kageaki, Takahata Yurina, Chiba Shunsuke, Fukushima Seina, Kameyama Yuko, Odagiri Haruka, Makiguchi Tomonori, Tanaka Hisashi, Tasaka Sadatomo
The Journal of the Japan Society for Respiratory Endoscopy 47 ( 5 ) 444 - 448 2025.9
-
J-REGISTER: real-world study of Japanese patients with EGFR mutation-positive NSCLC treated with first-line afatinib.
Yamaguchi T, Daga H, Tanaka H, Kijima T, Mizushima M
Future oncology (London, England) 21 ( 16 ) 2039 - 2052 2025.7
-
A Randomized Trial of Nutrition and Exercise Treatment in Patients With Pancreatic and Non-Small Cell Lung Cancer (NEXTAC-TWO).
Mitsunaga S, Naito T, Imai H, Kimura M, Miura S, Tanaka H, Mizukami T, Imoto A, Kondoh C, Okuyama H, Ueno M, Shiotsu S, Inano T, Chitose H, Tatematsu N, Okayama T, Mouri T, Sugiyama M, Omae K, Kawabata T, Mori K, Takayama K.
J Cachexia Sarcopenia Muscle. 2025.6
-
Prolonged progression-free survival on epidermal growth factor receptor-tyrosine kinase inhibitors predicts superior response to atezolizumab-based therapy over chemotherapy in epidermal growth factor receptor-mutated non-small-cell lung cancer following progression.
Morimoto K, Yamada T, Furuya N, Tanaka H, Yoshimura A, Oba T, Hibino M, Fukuda T, Goto Y, Nakao A, Ogusu S, Okazaki Y, Harada T, Ota T, Masubuchi K, Mikami K, Hata T, Matsumoto S, Honda R, Date K, Chihara Y, Takayama K
ESMO real world data and digital oncology 8 100152 2025.6
-
Association Between Baseline Neutrophil Count and Febrile Neutropenia Following Docetaxel and Ramucirumab With Prophylactic Pegfilgrastim.
Makiguchi T, Odagiri H, Tanaka H, Taima K, Tasaka S
Thoracic cancer 16 ( 11 ) e70099 2025.6
-
Prospective Multi-Institutional Observational Study of Retreatment with Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1/PD-L1 Plus Chemotherapy: NJLCG (North Japan Lung Cancer Group) Trial 1901.
Saito S, Kawashima Y, Tanaka H, Yoshimura N, Tsukita Y, Saito R, Nakagawa T, Inomata M, Nagashima H, Sugawara S
Cancers 17 ( 9 ) 2025.5
-
Impact of EGFR Mutation Subtypes on Response to Chemoimmunotherapy and Chemotherapy in Non-Small-Cell Lung Cancer After EGFR-TKI Failure.
Morimoto K, Yamada T, Furuya N, Tanaka H, Yoshimura A, Oba T, Hibino M, Fukuda T, Goto Y, Nakao A, Ogusu S, Okazaki Y, Harada T, Ota T, Masubuchi K, Mikami K, Hata T, Matsumoto S, Honda R, Date K, Chihara Y, Kawachi H, Takayama K
Targeted oncology 20 ( 3 ) 531 - 541 2025.5
-
Prognostic impact of oligometastasis in older patients with extensive-stage small cell lung cancer.
Morinaga D, Hashimoto K, Asahina H, Tanaka H, Honjo O, Harada T, Yokouchi H, Kikuchi H, Shigaki R, Takashina T, Nakamura K, Kawai Y, Takahashi M, Kida R, Sukoh N, Ito K, Takahashi A, Hommura F, Ohhara Y, Furuta M, Konno S, Hosomi Y, Oizumi S
Respiratory investigation 63 ( 3 ) 373 - 382 2025.5
-
Phase 2 Trial of Combination Radiotherapy and Pembrolizumab Plus Chemotherapy in Patients With Previously Untreated Metastatic NSCLC: NJLCG 1902.
Yoko Tsukita, Rei Umezawa, Taku Nakagawa, Akira Anbai, Tomonori Makiguchi, Hisashi Tanaka, Yosuke Horii, Aya Suzuki, Ryo Morita, Hitomi Nogawa, Hiroshi Yokouchi, Nozomu Kimura, Keiichi Jingu, Akira Inoue, Hisatoshi Sugiura, Eisaku Miyauchi
JTO clinical and research reports 6 ( 5 ) 100817 - 100817 2025.5
-
Recovery from rituximab-associated persistent hypogammaglobulinaemia in children with nephrotic syndrome.
Hirano D, Fujimaru T, Sako M, Tanaka S, Inaba A, Uchimura T, Kamei K, Kubota T, Ohta T, Okamoto T, Tanaka H, Hamada R, Ito S
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 40 ( 5 ) 967 - 977 2025.4
-
Plasma cell-free DNA methylation profile before afatinib treatment is associated with progression-free and overall survival of patients with epidermal growth factor receptor gene mutation-positive non-small cell lung cancer.
Fujimoto M, Yasuda H, Arai E, Nakajima M, Takata S, Morikawa K, Tanaka H, Itani H, Honda T, Horiuchi K, Watanabe K, Nakagawa H, Nakahara Y, Seki Y, Bessho A, Takahashi N, Hayashi K, Endo T, Takeyama K, Maekura T, Takigawa N, Kawase A, Endoh M, Nemoto K, Kishi K, Soejima K, Okuma Y, Togashi A, Matsutani N, Seki N, Kanai Y
Clinical epigenetics 17 ( 1 ) 63 2025.4
-
Mycobacterium goodii pulmonary disease in an immunocompetent patient: A case report and literature review.
Shiratori T, Nunomura Y, Itoga M, Makiguchi T, Tanaka H, Taima K, Chikamatsu K, Kurose A, Mitarai S, Tasaka S
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 31 ( 4 ) 102665 2025.4